Neurocrine Biosciences, Inc.

Please stand by. Your program is about to begin. Good day, everyone, and welcome to NeuroClean Biosciences Report's first quarter results. At this time, all participants are in a listen-only mode. Later, you will have the opportunity to ask questions during the question and answer session. You may register to ask questions by pressing the star and 1 on your telephone keypad. You may withdraw your question by pressing star 2. Please note this call is being recorded and I will be sending by should you need any assistance. It is now my pleasure to turn the conference over to Todd Tushla, Vice President of Investor Relations. Please go ahead.

Good morning, everyone, and welcome to NERC and Biosciences' first quarter 2024 earnings call. With me are Kevin Gorman, Chief Executive Officer, Matt Abernathy, Chief Financial Officer, Irie Roberts, Chief Medical Officer, Eric Benevich, Chief Commercial Officer, and Kyle Gano, Chief Business Development and Strategy Officer. We're also joined today by Dr. Jas Singh, Nurocrin's Vice President of Psychiatry Clinical Development, which includes serving as the program lead for NBI 845, our AMPA potentiator, which recently read out positive phase two top line results in adults with major depressive disorder. Jas has been at Nurocrin since 2020. Prior to joining Nurocrin, Jas spent 14 years at Johnson & Johnson, where among other things, he led the clinical efforts for the esketamine program through approval. I'm sure you'll have a few questions, not only for Jas, but also for Irie and Kyle today on the 845 program. With introductions complete, I'll remind you that we will be making forward-looking statements. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to review the risk factors discussed in our latest SEC filings. At this point, I'll turn the call over to Kevin.

Thank you, Todd. Good morning, everyone. We've had a remarkable week, and it's only Wednesday morning. We've submitted two NDAs on Kinesophant and received an FDA approval for a new offering of Ingresa. I'm thinking about giving the company the rest of the week off. You know, Neurocrine has never had the opportunity to positively impact so many lives as it has today. As you will hear in greater detail from Matt, Eric, and Irie, we are making progress in every aspect of our business focused on bringing life-changing medicines forward. We have never treated as many TD and HD patients as we are treating today. We have never had as deep a mid- and late-stage clinical pipeline. And now we have a good line of sight into a number of potentially new medicines coming into the clinic from our research group in the next two years, several of them with the promise of disease modification. Now, we're constantly prioritizing the funding of our programs based on data. We're in the enviable position to be able to support our current and future pipeline. Now, a recent example of a program that will be seeing increased funding is our AMPA-modulating molecule 845 as a treatment for major depression. The efficacy and tolerability seen in this trial is very compelling, and we will be meeting with FDA to further define the registration program. Now, in our press release this morning and in IRE's comments upcoming, we share more information on this trial. However, we will limit our comments on this data set as we file additional intellectual property and protect future publication opportunities. So, with those brief remarks, I'd like to turn it over to my colleagues, starting with Matt. Thanks, Kevin.